Literature DB >> 891611

Histamine, histamine antagonists and regional blood flow.

B M Johnston, D A Owen.   

Abstract

The effects of mepyramine, a selective histamine H1-receptor antagonist, and metiamide, a selective histamine H2-receptor antagonist, have been determined on the cardiovascular response to intravenous infusions of a large dose of histamine, 1 X 10(-7) mol/kg/min. Pretreatment with either mepyramine, 2.5 X 10(-6) mol/kg, or metiamide, 2 X 10(-6) mol/kg/min, had no significant effect on the fall in blood pressure or fall in total peripheral resistance during histamine infusion. Pretreatment with mepyramine, 2.5 X 10(-6) mol/kg, and metiamide, 2 X 10(-6) mol/kg/min, abolished the fall in blood pressure and total peripheral resistance during infusion of histamine. Histamine-induced vasodilatation in the stomach was unaltered by pretreatment with mepyramine but abolished by pretreatment with metiamide. Histamine-induced coronary vasodilation was reduced slightly by pretreatment with mepyramine and substantially by pretreatment with metiamide. Coronary vasodilatation was abolished by treatment with mepyramine and metiamide.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 891611     DOI: 10.1016/0014-2999(77)90310-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Histamine H1- and H2-receptor-mediated gastric microcirculatory effects in the aetiology of stress ulceration in the rat stomach.

Authors:  C H Cho; C W Ogle
Journal:  Experientia       Date:  1978-10-15

2.  Effects of histamine antagonists on noradrenaline-stimulated blood flow and oxygen consumption of brown adipose tissue in the rat.

Authors:  N J Rothwell; M J Stock; M G Wyllie
Journal:  Pflugers Arch       Date:  1984-11       Impact factor: 3.657

3.  Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats.

Authors:  Aydin Inan; Meral Sen; Onder Sürgit; Metin Ergin; Mikdat Bozer
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.